White House reaches first Most-Favored-Nation pricing deal, realigning U.S. drug costs to international benchmarks and reshaping payer and provider reimbursement strategies.

HHS has finalized a rule (HTI-4) to deliver real-time prescription drug price transparency at the point of care, giving clinicians and consumers visibility into patient-specific coverage, out-of-pocket costs, and prior authorization requirements through certified health IT. The move aims to reduce administrative burden, speed access to therapy, and support more cost-effective prescribing aligned with value-based care goals.

The U.S. Department of Health and Human Services (HHS) has finalized pivotal regulations designed to streamline e-prescribing and prior authorization processes. These new rules aim to enhance interoperability, reduce administrative burdens on healthcare providers, and improve patient care outcomes. As the healthcare landscape shifts towards value-based care, it is essential for decision-makers in healthcare organizations to align their systems with these changes to ensure compliance and optimize operational efficiency.